Mitochondrial transplantation may serve not only to bolster energetic capacity but can “prime” adaptable GBM cells for synthetic lethality when combined with redox-disrupting agents such as CPI-613 (PDH inhibitor), rotenone (Complex I inhibitor), or buthionine sulfoximine (GSH synthesis inhibitor) [16, 17]. The gene discussed is PDP1; the disease is glioblastoma.